Filing Flows › Cytokinetics (CYTK) › Q4 2025
Cytokinetics (CYTK) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Cytokinetics (CYTK) reported revenue of $17.8M for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +817% from the quarter before.
Cytokinetics, Q4 2025: revenue $17.8M (+5% year over year), net loss $183M, operating cash flow −$143M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.8M | +817% | +5% |
| Operating profit | −$178M | — | — |
| Net earnings | −$183M | — | — |
| Operating cash flow | −$143M | — | — |
What changed
Revenue was $17.8M in Q4 2025, up 5% year over year and up 817% from the previous quarter. License and Milestone Revenues was the largest line at 84% of revenue.
Operating costs exceeded revenue by $178.4M, an operating margin of -1004.6%. Total costs grew 26% against revenue growth of 5%. The fastest-growing cost line was General & admin (+47%). The quarter ended with a net loss of $183.0M, narrower than the previous quarter's $306.2M loss.
Operating cash flow was −$142.7M. Non-cash charges added back $2.9M of depreciation and amortization and $30.5M of share-based compensation. Capital expenditures of $5.6M exceeded it, leaving free cash flow of −$148.3M.
Questions
What was Cytokinetics' revenue in the fourth quarter 2025?
Cytokinetics (CYTK) reported revenue of $17.8M for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +817% from the quarter before.
Source: Cytokinetics 10-K on SEC EDGAR.